CHENGDU, China I 8, 2025 I Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has ...

Nasal irrigation can be a useful addition to the management of chronic upper respiratory conditions, including nasal ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- A few baseline characteristics can predict the need for recurrent endoscopic sinus ...

The global laser-assisted ENT surgery market Share is projected to grow from US$ 254.14 million in 2023 to US$ 513.78 million by 2031, with a CAGR of 9.2%. The growth is fueled by the increasing ...

Nasal microbiota transplantation could revolutionise the treatment of chronic rhinosinusitis and respiratory tract infections ...

Oxidative stress plays a critical role in the pathogenesis of upper and lower respiratory tract diseases, such as chronic rhinosinusitis with nasal polyps (CRSwNP), allergic rhinitis (AR), and asthma ...

The nasal microbiota acts as a first line of defence. When this balance is disrupted, it can pave the way for inflammation ...

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

The probability of revision sinus surgery including removing nasal polyps is higher if the patient has asthma or is on ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...